In Vivo Imaging of Spinal Cord Astrocyte and Axon Injury
Laminectomy surgeries were performed as previously described21: Mice were anesthetized by an intraperitoneal injection of ketamine‐xylazine (87mg/kg/13mg/kg, respectively) or meditomidin 0.5mg/kg, midazolam 5mg/kg, and fentanyl 0.05mg/kg. Anesthesia was reapplied as needed (every 60–120 minutes). After a double dorsal laminectomy over the fourth lumbar, L4, and L5 segments, mice were suspended using compact spinal cord clamps.30 A well around the opening was built using 2‐4% agarose to hold aCSF (as above, glucose omitted or alternatively, in mM: 148.2 NaCl, 3.0 KCl, 0.8 Na2HPO4, 0.2 NaH2PO4, 1.4 CaCl2, and 0.8 MgCl2). An imaging window free from dura was established in the imaging area using a bent hypodermic needle. In some experiments, astrocyte death was verified by addition of ethidium homodimer‐1 (1:500, 0.56mg/ml stock; Invitrogen, Carlsbad, CA). In vivo imaging of the lumbar spinal cord was performed as previously described.21, 31 Briefly, stacks were acquired using two‐photon microscopes (Olympus FV1000 MPE or FVMPE‐RS tuned to 910 nm for green fluorescent protein [GFP] alone and 980nm for GFP/OFP [orange fluorescent protein], equipped with a ×25/1.05 N.A. water‐dipping cone objective). All light was first filtered through a 690 nm short‐pass dichroic mirror. Fluorescence was collected using a G/R filter set (BA 495‐540, BA 570‐625) mounted in front of gallium arsenide phosphide photomultiplier tubes. Time‐lapse stacks were acquired at 3‐minute intervals for 3 hours (astrocyte loss) or at 15‐minute intervals for 6 hours (axon damage) with the following parameters: 35 images (zoom 1.8–2.0; pixel size: 0.28–0.38 µm) with 1‐µm z‐step. Diluted heat‐inactivated serum/plasma was applied every 30 minutes, supplemented with 20% of non‐heat‐inactivated HD serum as a complement source. Compared to experiments with acute brain slices, a higher concentration was needed, most likely because of restricted penetration and possibly the presence of complement blockers in vivo. Serum/plasma was present in the spinal opening for the initial 90 minutes of the experiment, after which it was replaced with aCSF (at 90 minutes and renewed every 60 minutes until the end of the experiment). Transient delivery of the NMO sample and complement source was designed to induce an acute, well‐defined injury and reduce consumption of sparse patient‐samples. In a set of control experiments using NMO1 samples and HD serum for up to 8 hours continuously, we found no qualitative difference between prolonged and transient applications, although, as expected, astrocyte depletion and the degree of axon swellings was more pronounced after longer exposure to patient IgG and complement. To confirm AQP4 specificity, we also performed experiments using a human IgG1 recombinant antibody rAb 7‐5‐53 reconstructed from a clonotypic plasma blast obtained from the CSF of an NMO patient (r‐AQP4‐IgG)9. r‐AQP4‐IgG was applied at 1.5 μg/ml of IgG supplemented with 20% of non‐heat‐inactivated HD serum. The rAb ICOS‐5‐2, a divalent human IgG1 antibody of unknown specificity, developed from a chronic meningitis patient, served as an isotype control (r‐ctrl‐IgG). We have previously demonstrated that phototoxicity does not appear to have a measurable impact on the health of spinal axons under such imaging conditions.21, 22, 31, 32 Moreover, histological analysis confirmed NMO serum‐/plasma‐mediated astrocyte loss in the absence of oligodendrocyte loss in superficial spinal cord layers when no imaging was done (see below and cf. Fig 1G,H). Additionally, axonal pathology could be confirmed in experiments in which only an initial and a final image (at 6 hours) were taken (cf. Fig 4B). To rule out a spurious influence of the transgenic labeling of axons, we performed experiments without imaging using wild‐type (C57BL/6) and transgenic animals and antitubulin staining (see below). The analysis was performed by a scorer blind to the treatment conditions and genotypes and showed a comparable percentage of axonal swellings in spinal cords treated with NMO serum/plasma irrespective of genotype (data not shown).
Partial Protocol Preview
This section provides a glimpse into the protocol. The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Herwerth M., Kalluri S.R., Srivastava R., Kleele T., Kenet S., Illes Z., Merkler D., Bennett J.L., Misgeld T, & Hemmer B. (2016). In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica‐related pathology. Annals of Neurology, 79(5), 794-805.
Publication 2016
Corresponding Organization : Munich Cluster for Systems Neurology
Other organizations :
University of Pecs, University of Southern Denmark, Odense University Hospital, University of Geneva, University Hospital of Geneva, University of Göttingen, University of Colorado Denver, German Center for Neurodegenerative Diseases, Center for Integrated Protein Science Munich
Anesthesia type (ketamine-xylazine or medetomidine-midazolam-fentanyl)
Presence or absence of serum/plasma (with or without complement)
Type of antibody applied (r-AQP4-IgG or r-ctrl-IgG)
dependent variables
Astrocyte loss
Axon damage (swellings)
control variables
Lumbar spinal cord region (L4-L5 segments)
Imaging parameters (zoom, pixel size, z-step)
Duration of imaging (3 hours for astrocyte loss, 6 hours for axon damage)
Frequency of imaging (3-minute intervals for astrocyte loss, 15-minute intervals for axon damage)
Application of serum/plasma (first 90 minutes, then replaced with aCSF)
positive controls
NMO1 sample and HD serum (applied for up to 8 hours continuously)
R-AQP4-IgG (1.5 μg/ml) with 20% non-heat-inactivated HD serum
negative controls
R-ctrl-IgG (divalent human IgG1 antibody of unknown specificity)
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to
get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required